Antiplatelet drugs in cardiovascular prevention: take adverse effects and costs into account.
(1) Several antiplatelet drugs have proven preventive efficacy, including aspirin, aspirin + dipyridamole, clopidogrel, ticlopidine and flurbiprofen. They differ mainly in their adverse effects and costs. (2) Aspirin has essentially gastrointestinal adverse effects, whose incidence can be limited by prescribing a daily dose below 350 mg.  (3) The addition of dipyridamole to aspirin can cause headache and diarrhoea. (4) Ticlopidine should be avoided because of the risk of agranulocytosis.  (5) Adverse effects are less frequent and less severe with clopidogrel than with ticlopidine.  (6) Like other nonsteroidal antiinflammatory drugs, flurbiprofen has mainly gastrointestinal adverse effects.  (7) Treatment is least costly with low-dose aspirin and most costly with clopidogrel.
D001241:Aspirin / Q000191:economics / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000517:prevention & control / Q000628:therapy; D003362:Cost-Benefit Analysis; D004176:Dipyridamole / Q000191:economics / Q000627:therapeutic use; D016527:Drug Costs; D005480:Flurbiprofen / Q000191:economics / Q000627:therapeutic use; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use; D013988:Ticlopidine / Q000037:antagonists & inhibitors / Q000191:economics / Q000627:therapeutic use
D010975:Platelet Aggregation Inhibitors; D005480:Flurbiprofen; D004176:Dipyridamole; D013988:Ticlopidine; D001241:Aspirin